EFPIA：2026年通过一家小企业的视角，阐述欧洲作为投资地的吸引力正在下降报告（英文版）

While the European biotechnology industry has been growing, there are concerns about European competitiveness and whether Europe is lagging behind other global regions in terms of investment, manufacturing, and commercialization • European pharmaceutical firms face structural barriers affecting investment decisions in clinical development, regulation, and manufacturing. For smaller firms, which play a vital role in innovation, these barriers may be exacerbated • The European Biotech Act, prop